Clinical Trial

A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This integrated Ph1/2 clinical study is to assess the safety, tolerability and pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of OCT-980 in healthy volunteers and participants with RHO-adRP.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-20
notable Enrollment reduced: 50 -> 32 participants 2026-05-20
Trial Details
NCT Number NCT07408232
Lead Sponsor Octant, Inc.
Conditions Retinitis Pigmentosa
Enrollment 32 participants
Start Date 2026-03-10
Primary Completion 2028-11-01 (estimated)
Study Completion 2028-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-19